WO2026022745 - USE OF DNA-PK INHIBITOR FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS IN COMBINATION WITH RADIOTHERAPY
National phase entry is expected:
Publication Number
WO/2026/022745
Publication Date
29.01.2026
International Application No.
PCT/IB2025/057491
International Filing Date
24.07.2025
Title **
[English]
USE OF DNA-PK INHIBITOR FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS IN COMBINATION WITH RADIOTHERAPY
[French]
UTILISATION D'UN INHIBITEUR DE L'ADN-PK POUR LE TRAITEMENT DE TUMEURS DU SYSTÈME NERVEUX CENTRAL EN COMBINAISON AVEC UNE RADIOTHÉRAPIE
Applicants **
KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD.
Inventors
WEI, Yonggang
SUN, Yi
YE, Fei
Priority Data
202410998510.6
24.07.2024
CN
202411355781.6
27.09.2024
CN
202411381044.3
30.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2989 | |
| EPO | Filing, Examination, Granting | 20628 | |
| Japan | Filing, Examination, Granting | 2864 | |
| South Korea | Filing, Examination, Granting | 3583 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
38,404
Contact Us
Abstract[English]
The present disclosure provides the use of a DNA-PK inhibitor (e.g., a compound represented by formula (I)) for the treatment of a tumor (e.g., central nervous system tumors) in combination with radiotherapy (I).[French]
La présente divulgation concerne l'utilisation d'un inhibiteur d'ADN-PK (par exemple, un composé représenté par la formule (I)) pour le traitement d'une tumeur (par exemple, des tumeurs du système nerveux central) en combinaison avec une radiothérapie (I).